Results 111 to 120 of about 14,451 (146)
Some of the next articles are maybe not open access.
The metabolism of synthetic estrogens in non-users and users of oral contraceptives
Steroids, 1975Using both pulse injections and constant infusions of 3-H-mestranol (3H-ME) (1) and 3-H-ethinyl estradiol (3H-EE) we have studied the metabolism of these compounds in non-users and users of oral contraceptives. Following pulse injection of 3-H-ME the disappearance of radioactivity could be described as a function which was the sum of two exponentials ...
Christopher Longcope +1 more
openaire +2 more sources
Neurological syndromes occurring in patients receiving synthetic steroids (oral contraceptives)
Neurology, 1966Case studies of 34 women with neurological syndromes associated with oral contraceptive use are discussed with a view to identifying contraindications of progestational steroid use. The patients were classified by occlusive cerebral arterial disease (5 patients) cortical vein thrombosis (1 patient) and vascular headaches (28 patients).
Peritz Scheinberg, Sherif Shafey
openaire +3 more sources
Science of The Total Environment, 2011
Synthetic oral contraceptives (SOCs) are a group of compounds with progestagenic and/or androgenic activities, with some also possessing estrogenic activities. Recent research has documented that some of these emerging contaminants have adverse effects on aquatic organisms at very low concentrations.
Zehua Liu +3 more
openaire +3 more sources
Synthetic oral contraceptives (SOCs) are a group of compounds with progestagenic and/or androgenic activities, with some also possessing estrogenic activities. Recent research has documented that some of these emerging contaminants have adverse effects on aquatic organisms at very low concentrations.
Zehua Liu +3 more
openaire +3 more sources
Residual vascular risk of discontinued oral contraception
Atherosclerosis, 1985Recent epidemiological data indicate that the risk of thromboembolic disease associated with oral contraception (OC) may persist after discontinuation of the drug. It was demonstrated on the other hand that antibodies to sex steroid hormones which develop in OC users, were significantly correlated with the incidence of thrombosis. It is well known that
F. Doucet +3 more
openaire +3 more sources
Teratology, 1983
AbstractThirty timed‐mated pregnant rhesus monkeys received Norlestrin (Norethindrone acetate, 2.5 mg, and ethinyl estradiol, 0.05 mg pertablet, Parke‐Davis) orally at four different dose levels. The dose levels were 5, 10, 25 and 50 mg/day/monkey and the doses were administered during early (days 21–35), late (days 33–46), and throughout (days 21–46 ...
Andrew G Hendrickx, S. Prahalada
openaire +3 more sources
AbstractThirty timed‐mated pregnant rhesus monkeys received Norlestrin (Norethindrone acetate, 2.5 mg, and ethinyl estradiol, 0.05 mg pertablet, Parke‐Davis) orally at four different dose levels. The dose levels were 5, 10, 25 and 50 mg/day/monkey and the doses were administered during early (days 21–35), late (days 33–46), and throughout (days 21–46 ...
Andrew G Hendrickx, S. Prahalada
openaire +3 more sources
Contraception, 1977
Abstract The metabolic fate of isotopically labelled ethynylestradiol (EE) and its 3-methyl ether, mestranol (MEE), was investigated in three baboons who were receiving a norethindrone-mestranol combination oral contraceptive (C.O.C.) and the results compared to those previously obtained from the same baboons before receiving the C.O.C.
T.D. Avila +2 more
openaire +3 more sources
Abstract The metabolic fate of isotopically labelled ethynylestradiol (EE) and its 3-methyl ether, mestranol (MEE), was investigated in three baboons who were receiving a norethindrone-mestranol combination oral contraceptive (C.O.C.) and the results compared to those previously obtained from the same baboons before receiving the C.O.C.
T.D. Avila +2 more
openaire +3 more sources
Contraception, 1978
Two combined oral contraceptives, one containing ethinyl estradiol and the other micronized estradiol and estriol, were compared by measuring a variety of endocrine and renal parameters over nine months. Significant changes were observed in plasma renin activity (P.R.A.) on the synthetic estrogen.
D.M. Saunders +2 more
openaire +3 more sources
Two combined oral contraceptives, one containing ethinyl estradiol and the other micronized estradiol and estriol, were compared by measuring a variety of endocrine and renal parameters over nine months. Significant changes were observed in plasma renin activity (P.R.A.) on the synthetic estrogen.
D.M. Saunders +2 more
openaire +3 more sources
Acta Endocrinologica, 1978
ABSTRACT Increases in serum triglycerides, cholesterol and pre-β- and β-lipoproteins have been considered as significant pathogenic factors regarding the possible thrombotic side-effect of treatment with oral contraceptives of the combined type containing synthetic oestrogen.
L. Hemmingsen +4 more
openaire +3 more sources
ABSTRACT Increases in serum triglycerides, cholesterol and pre-β- and β-lipoproteins have been considered as significant pathogenic factors regarding the possible thrombotic side-effect of treatment with oral contraceptives of the combined type containing synthetic oestrogen.
L. Hemmingsen +4 more
openaire +3 more sources
International Journal of Oncology, 2005
Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including breast carcinomas that is associated with poor prognosis. In this study, we explored whether breast-cancer associated FAS (oncogenic antigen-519) is regulated by the progestin component in oral contraceptives.
Bharvi P. Oza +3 more
openaire +3 more sources
Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including breast carcinomas that is associated with poor prognosis. In this study, we explored whether breast-cancer associated FAS (oncogenic antigen-519) is regulated by the progestin component in oral contraceptives.
Bharvi P. Oza +3 more
openaire +3 more sources
Klinische Wochenschrift, 1973
Mit dem synthetisierten LH-Releasing-Faktor1 last sich in einer Dosis von 50 µg zwischen dem 22. und 26. Cyclustag eine LH- und FSH-Ausschuttung wie zur Zeit der Ovulation erzielen. Unter Gabe eines definierten Ovulationsblockers blieb bei den gleichen Frauen trotz LH-Releasing-Faktor in gleicher Dosis der zur Zeit der Ovulation beobachtete Anstieg der
A. Reuter +3 more
openaire +4 more sources
Mit dem synthetisierten LH-Releasing-Faktor1 last sich in einer Dosis von 50 µg zwischen dem 22. und 26. Cyclustag eine LH- und FSH-Ausschuttung wie zur Zeit der Ovulation erzielen. Unter Gabe eines definierten Ovulationsblockers blieb bei den gleichen Frauen trotz LH-Releasing-Faktor in gleicher Dosis der zur Zeit der Ovulation beobachtete Anstieg der
A. Reuter +3 more
openaire +4 more sources